- Asymmetric Synthesis of Corey Lactone and Latanoprost
-
Corey lactone was synthesized in a single pot within 152 minutes in a 50 % overall yield via pot and time economical manner. Latanoprost, an antiglaucoma blockbuster drug, was also synthesized via seven pot reaction with five purifications in a 25 % total yield. One of the key reactions is asymmetric domino Michael/Michael reaction, formal [3+2] cycloaddition reaction, of 3-(dimethylphenylsilyl)propenal and ethyl 4-oxo-2-pentenoate, catalyzed by diphenylprolinol silyl ether, which constructed the core substituted cyclopentanone derivative with nearly optically pure form.
- Hayashi, Yujiro,Umekubo, Nariyoshi
-
p. 6221 - 6227
(2020/09/21)
-
- NOVEL LATANOPROST INTERMEDIATE AND METHOD FOR PREPARING LATANOPROST WITH HIGH PURITY
-
The present invention provides a novel latanoprost intermediate represented by chemical formula 1. In chemical formula 1, R is hydrogen or C_1-C_4 alkyl, P is hydrogen or a hydroxy protecting group, at least one P is a hydroxy protecting group. The hydroxy protecting group is represented by chemical formula 2. In chemical formula 2, R^1 is each independently -NO_2 or C_6-C_18 aryl, and R^1 is fused to a phenyl ring to form a C_10-C_18 aromatic ring.COPYRIGHT KIPO 2021
- -
-
Paragraph 0052; 0062-0064
(2020/10/21)
-
- Access to a Key Building Block for the Prostaglandin Family via Stereocontrolled Organocatalytic Baeyer–Villiger Oxidation
-
A new protocol for the construction of a crucial bicyclic lactone of prostaglandins using a stereocontrolled organocatalytic Baeyer–Villiger (B-V) oxidation was developed. The key B-V oxidation of a racemic cyclobutanone derivative with aqueous hydrogen peroxide has enabled an early-stage construction of a bicyclic lactone skeleton in high enantiomeric excess (up to 95 %). The generated bicyclic lactone is fully primed with two desired stereocenters and enabled the synthesis of the entire family of prostaglandins according to Corey′s route. Furthermore, the reactivity and enantioselectivity of B-V oxidation of racemic bicyclic cyclobutanones were evaluated and 90–99 % ee was obtained, representing one of the most efficient routes to chiral lactones. This study further facilitates the synthesis of prostaglandins and chiral lactone-containing natural products to promote drug discovery.
- Zhu, Kejie,Hu, Sha,Liu, Minjie,Peng, Haihui,Chen, Fen-Er
-
p. 9923 - 9927
(2019/05/16)
-
- An improved synthesis of latanoprost involving effective control on 15(S) diastereomer
-
An improved process for the synthesis of latanoprost having excellent optical purity (de 99.9%, [α]D20 = +35.37° (c = 0.90, acetonitrile)) without use of preparative HPLC is described. This process involves effective purification of hydroxyl intermediate (5A) through solvent crystallization followed by inhibition of inversion of the chiral center at C-15 position. This was possible due to judicious use of diol intermediate (6) for double bond reduction prior to hydroxyl protection.
- Sasane, Sachin A.,Bhise, Nandu B.,Singh, Girij P.,Joseph, Alex,Shenoy, Gautham G.
-
p. 2350 - 2356
(2019/07/31)
-
- Enantio- and Diastereoselective Synthesis of Latanoprost using an Organocatalyst
-
An enantioselective total synthesis of latanoprost was achieved. Its chiral cyclopentane core structure was constructed through an organocatalyst-mediated [3+2]-cycloaddition reaction, and chirality in the ω-side chain was generated by prolinate-anion-mediated α-aminoxylation of an aldehyde. Highly diastereoselective domino acetalization and an oxy-Michael reaction were key steps for the generation of C9 chirality.
- Kawauchi, Genki,Umemiya, Shigenobu,Taniguchi, Tohru,Monde, Kenji,Hayashi, Yujiro
-
p. 8409 - 8414
(2018/05/30)
-
- High-purity Latanoprost, preparation method therefor and use of Latanoprost
-
The invention discloses high-purity Latanoprost, a preparation method therefor and use of the Latanoprost. According to the high-purity Latanoprost disclosed by the invention, the content of an impurity with a structure represented by a formula II shown in the description in the high-purity Latanoprost is not higher than 0.1%. The preparation method comprises the steps: (1) subjecting a compound represented by a formula IV shown in the description (an intermediate 1 of the Latanoprost) to a wittig reaction, so as to obtain a compound represented by a formula V shown in the description (an intermediate 2 of the Latanoprost); (2) subjecting the compound V to washing and purifying by a ammonium chloride solution, then, carrying out dehydroxylation protection or not, and carrying out a reaction with iodo-isopropane, so as to obtain a crude raw pharmaceutical material of the Latanoprost; and (3) loading a sample of the raw pharmaceutical material of the Latanoprost to a silica-gel column, carrying out eluting with an eluate, and carrying out chromatographic purification, thereby obtaining the high-purity Latanoprost.
- -
-
-
- A Facile and Efficient Synthesis of (15R)-Latanoprost from Chiral Precursor Corey Lactone Diol
-
An efficient asymmetric synthetic route for the synthesis of anti-glaucoma agent, (15R)-latanoprost using Corey lactone diol as chiral substrate under Swern oxidation, allylic reduction and Wittig reaction conditions has been developed. In this method, reduction of keto and alkene functional groups has been achieved in a single step using low cost catalyst NiCl2/NaBH4 in methanol. This new synthetic protocol is a good alternative for the synthesis of latanoprost with high stereo selectivity and improved yield. [Figure not available: see fulltext.]
- Vijendhar,Srinivas,Boodida, Sathyanarayana
-
p. 2023 - 2028
(2015/12/30)
-
- NEW PROCESS FOR THE PREPARATION OF HIGH PURITY PROSTAGLANDINS
-
The subject of the invention is a process for the preparation of high purity prostaglandin acid of the general formula II wherein the bonds marked with dotted lines represent single or double bonds wherein the double bonds may be cis- or trans oriented, Y represents 0 or CH 2, and R3 stands for a phenyl group which is optionally substituted with CF3, wherein the crude prostaglandin acid of the general formula II is purified by normal phase silicagel chromatography.
- -
-
Page/Page column 17
(2015/10/05)
-
- Synthesis of prostaglandin analogues, latanoprost and bimatoprost, using organocatalysis via a key bicyclic enal intermediate
-
Two antiglaucoma drugs, bimatoprost and latanoprost, which are analogues of the prostaglandin, PGF2?±, have been synthesized in just 7 and 8 steps, respectively. The syntheses employ an organocatalytic aldol reaction that converts succinaldehyde into a key bicyclic enal intermediate, which is primed for attachment of the required lower and upper side chains. By utilizing the crystalline lactone, the drug molecules were prepared in >99% ee.
- Pr??vost, S??bastien,Thai, Karen,Sch??tzenmeister, Nina,Coulthard, Graeme,Erb, William,Aggarwal, Varinder K.
-
supporting information
p. 504 - 507
(2015/03/05)
-
- Compound And Method
-
A compound of formula (I): (I) wherein Y is, Z is OR10, NR11R11 SR11, S(0)R11 S02R11, R10 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO—R11, or a protecting group, and R11 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl; a process for making a compound of formula (I); and a process for making a prostaglandin or a prostaglandin analogue using a compound of formula (I). wherein Y is
- -
-
Paragraph 0490-0496
(2015/06/17)
-
- Processes for the preparation of isomer free prostaglandins
-
Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R2, R3 and R4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.
- -
-
Paragraph 0174; 0175; 0176; 0177; 0178
(2015/03/03)
-
- PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS
-
Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R2, R3 and R4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.
- -
-
Paragraph 0174; 0175; 0176; 0177
(2015/02/25)
-
- PROCESS FOR THE PREPARATION OF TRAVOPROST
-
The subject of the invention is process the preparation of travoprost of formula (I) characterized by that the free acid of formula (II) is a. ) activated with 2-chloro-l,3-dimethylimidazolinium chloride (DMC) and the resulting activated carboxylic acid intermediate is reacted with isopropyl alcohol, or b. ) reacted with alkyl haloformate and the resulting mixed anhydride is reacted with isopropyl alcohol, or c. ) activated with a straight or branched C1-8 dialkyl dicarbonate and reacted with isopropanol in the presence of water-free magnesium salt.
- -
-
Page/Page column 10-11
(2014/06/23)
-
- COMPOUND AND METHOD
-
A compound of formula (I): (I) wherein Y is, Z is OR10, NR11R11 SR11, S(0)R11 S02R11, R10 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO-R11, or a protecting group, and R11 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl; a process for making a compound of formula (I); and a process for making a prostaglandin or a prostaglandin analogue using a compound of formula (I).
- -
-
Page/Page column 97; 98
(2014/01/08)
-
- Process for the synthesis of prostaglandins and intermediates thereof
-
A process is disclosed for the preparation of prostaglandins of the PGF2α-series, in particular Latanoprost, Bimatoprost and Travoprost, which are active in the treatment of ocular hypertensive conditions and glaucoma. The invention also relates to novel intermediates involved in the synthesis of these prostaglandin-PGF2α derivatives.
- -
-
-
- PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES
-
The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use in the preparation of prostagblandin derivatives.
- -
-
-
- PHOSPHATE-FREE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GLAUCOMA
-
The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid.
- -
-
-
- A NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF
-
This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and (CH2)nOR2 wherein n is from 1 to 3 and R2 represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and R1 is selected from OR3 and NHR3 wherein R3 is C1-C6 alkyl, H; and dashed lines represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.
- -
-
-
- PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS
-
A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.
- -
-
-
- SYNTHESIS OF PROSTANOIDS
-
The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs.
- -
-
-
- PROCESS FOR PREPARING PROSTAGLANDIN DERIVATIVES
-
The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.
- -
-
Paragraph 114-116
(2010/10/03)
-
- PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES
-
The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use in the preparation of prostaglandin derivatives.Said process comprises: a) reacting compounds of formula (I) with compounds of formula (II) to give compounds of formula (III) b) reducing with an asymmetric reducing agent the oxo group of the side chain of compounds of formula (III) to give compounds of formula (IV)
- -
-
Page/Page column 22
(2010/09/17)
-
- AMINO ACID SALTS OF PROSTAGLANDINS
-
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
- -
-
Page/Page column 15
(2010/05/13)
-
- AMINO ACID SALTS OF PROSTAGLANDINS
-
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
- -
-
Page/Page column 17
(2010/05/13)
-
- The Meyer-Schuster rearrangement: A new synthetic strategy leading to prostaglandins and their drug analogs, Bimatoprost and Latanoprost
-
Gold(I) mediated Meyer-Schuster rearrangement for the installation of the 'lower' side chain of prostaglandins and their analogs has been developed. This Au-mediated rearrangement, featuring a low catalyst loading and mild reaction conditions, has been demonstrated to be an efficient alternative to the standard Horner-Wadsworth-Emmons reaction in prostaglandin chemistry. Moreover, the present results provide a new synthetic process leading to pharmacologically active prostanoids: Latanoprost and Bimatoprost, that continue to hold key positions in the anti-glaucoma drug market.
- Zanoni, Giuseppe,D'Alfonso, Alessandro,Porta, Alessio,Feliciani, Lazzaro,Nolan, Steven P.,Vidari, Giovanni
-
experimental part
p. 7472 - 7478
(2010/12/25)
-
- Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
-
The present invention relates to an improved process for the production of prostaglandins and prostaglandin analogs. In particular, this invention relates to the production of prostaglandins of the PGF2α-series, including latanoprost, travoprost, and bimatoprost, which are active pharmaceutical ingredients used for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.
- -
-
Page/Page column 55-56
(2010/01/29)
-
- IMPROVED PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND ANALOGUES THEREOF
-
The present invention relates to an improved process for the preparation of prostaglandin and prostaglandin analogues, particularly PGF2α derivatives.
- -
-
Page/Page column 17
(2010/11/03)
-
- SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION
-
The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
- -
-
-
- Method for preparing prostaglandin F analogue
-
A method for preparing a prostaglandin F analogue represented by the following formula (I) is disclosed, wherein R1, and are as defined in the specification.
- -
-
Page/Page column 12
(2009/10/21)
-
- METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE
-
A method for preparing a prostaglandin derivative represented by the following general formula (I): (wherein Ph represents phenyl group, R1 represents a C1-7 alkyl group, a C1-7 alkenyl group, phenyl group, or benzyl group), which comprises the successive steps (1) to (8) described in the specification, or any one step or two or more successive steps selected from the group consisting of the steps (1) to (8). A method for efficiently, inexpensively and safely preparing prostaglandin derivatives, of which typical example is latanoprost, is provided.
- -
-
Page/Page column 7
(2008/06/13)
-
- Method for preparing prostaglandin derivative
-
A method for preparing a prostaglandin derivative represented by the following general formula (I): (wherein Ph represents phenyl group, R1 represents a C1-7 alkyl group, a C1-7 alkenyl group, phenyl group, or benzyl group), which comprises the successive steps (1) to (8) described in the specification, or any one step or two or more successive steps selected from the group consisting of the steps (1) to (8). A method for efficiently, inexpensively and safely preparing prostaglandin derivatives, of which typical example is latanoprost, is provided.
- -
-
Page/Page column 10
(2008/06/13)
-
- A new synthetic approach to high-purity (15R)-latanoprost
-
This paper describes a new synthesis of latanoprost (1) that afforded high purity latanoprost in 16.9 % overall yield in eight synthetic steps from sulfone 4. The "a chain" in a derivative of the (-)-"Corey lactone" was elongated first, followed by the attachment of a novel, enantiomerically pure "ω chain" synthon. This ensured the absence of the undesired (15S)-1 diastereomer in the synthesized prostaglandin. The crystalline nature of the novel sulfone 4 facilitated its purification. A variation of the new synthesis of latanoprost is described, where the laboratory-scale synthesis was further adapted to a hundred-gram scale. In the course of the present synthesis, a new prostaglandin sulfone intermediate, 21, which may find application in the synthesis of diverse prostaglandin analogs, was introduced. A practical synthesis of novel, enantiomerically pure "ω chain" synthons 15, 16, and 17 has also been carried out, employing diol 12, which was obtained from derivatives of the D-mannitol chiral pool. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.
- Martynow, Jacek G.,Jozwik, Julita,Szelejewski, Wieslaw,Achmatowicz, Osman,Kutner, Andrzej,Wisniewski, Krzysztof,Winiarski, Jerzy,Zegrocka-Stendel, Oliwia,Golebiewski, Piotr
-
p. 689 - 703
(2007/10/03)
-
- Processes and intermediates for the preparations of prostaglandins
-
The present invention provides novel processes for the preparation of a cyclopentanone of Formula II and a lactone of Formula I, which are useful in the production of prostaglandins: wherein Z, R2, R3, X1, X2, and are as defined in the specification. The invention also provides novel enantiomerically enriched compounds.
- -
-
Page/Page column 15-16
(2008/06/13)
-
- Novel intermediate compound for the preparation of prostaglandin F analogue
-
A method for the preparation of a prostaglandin F analogue presented by the following formula (I): is disclosed, wherein R1, G1, and are as defined in the specification. A novel intermediate compound for the preparation of a prostaglandin F analogue is also disclosed.
- -
-
Page/Page column 13
(2010/11/27)
-
- Processes and intermediates for the preparations of prostaglandins
-
The present invention provides novel processes for the preparation of a cyclopentanone of Formula II and a lactone of Formula I, which are useful in the production of prostaglandins: wherein Z, R2, R3, X1, X2, and ------------ are as defined in the specification. The invention also provides novel enantiomerically enriched compounds.
- -
-
Page/Page column 22-23
(2010/11/28)
-
- PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES
-
Invention relates to the process for preparation of 13,14-dihydro-PGF2α derivatives of R or S configuration at carbon atom in omega chain substituted by hydroxyl, represented by formula (I), wherein the meaning of substituents is defined in the description. Compounds (I) are valuable biologically active substances or intermediates thereof. The invention especially relates to the process for preparation of 13,14-dihydro-15(R)-17-substituted-18,19,20-trinor-PGF2α, ie. latanoprost.
- -
-
Page/Page column 107; 108
(2008/06/13)
-
- Process for the synthesis of prostaglandin derivatives
-
An alternative method for the synthesis of prostaglandin F analogues, in particular, analogues of PGF2α and specifically for the synthesis of latano-prost, wherein the transformation of the lactone intermediate (5) into the corresponding lactol (7) is carried out by treating the lactone intermediate (5) with a silane, preferably polymethylhydrosiloxane (PMHS), in the presence of a titanocene - and preferably titanocene fluoride. The method enables considerable production economies with respect to the conventional reduction of lactone with diisobutylaluminum hydride (DIBAL-H).
- -
-
Page/Page column 4; 16; 19; 22
(2010/11/24)
-
- Method and intermediate for preparing a prostaglandin F-type compound
-
A method for preparing a prostaglandin F-type compound. Also disclosed is an intermediate of the following formula (II) compound wherein R′, X and A have the same meaning as given in the specification.
- -
-
Page/Page column 14-15
(2010/10/20)
-
- Process for the preparation of prostaglandin derivatives
-
The invention provides a novel process for the preparation of prostaglandins and analogues thereof, and new crystalline intermediates in the process.
- -
-
-
- PROSTAGLANDIN SYNTHESIS
-
A process for the preparation of prostaglandin compounds having the formula (I); wherein A is selected from the group consisting Of C1-C6 alkyl; C7-C16 aralkyl wherein the aryl group is optionally substituted with one to three substituents selected from the group consisting Of C1 -C6 alkyl, halo and CF3; and (CH2)nOR' wherein n is from 1 to 3 and R' represents a C6-Cl0 aryl group which is optionally substituted with one to three substituents selected from the group consisting Of C1-C6 alkyl, halo and CF3; B is selected from OR" and NHR" wherein R" is C1-C6 alkyl; and formula (a) represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.
- -
-
Page/Page column 45-46
(2008/06/13)
-
- Prostaglandin synthesis
-
A process for the preparation of prostaglandin compounds having the formula (I): wherein A is selected from the group consisting of C1-C6 alkyl groups; C7-C16 aralkyl groups wherein an aryl portion thereof is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; and (CH2)nOR′ wherein n is an integer from 1 to 3 and R′ represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; B is selected from OR″ and NHR″ wherein R″ is C1-C6 alkyl groups; and represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.
- -
-
Page/Page column 40-41
(2010/02/12)
-
- Process and intermediates to prepare latanoprost
-
The present invention is a novel intermediate, compound of the formula (VI) and salts thereof. In addition, the invention includes a process for the preparation of a prostaglandin intermediates compounds (IV) and (XVIII) which comprises (1) contacting a the corresponding enone with (-)-chlorodiisopinocampheylborane while maintaining the reaction mixture temperature in the range of from about ?50° to about 0° and (2) contacting the reaction mixture of step (1) with a boron complexing agent.
- -
-
-
- Process and intermediates to prepare latanoprost
-
The present invention is a novel intermediate, compound of the formula (VI) and salts thereof. In addition, the invention includes a process for the preparation of a 15(S)-prostaglandin intermediates compounds (IV) and (XVIII) which comprises (1) contacting a the corresponding enone with (-)-chlorodiisopinocampheylborane while maintaining the reaction mixture temperature in the range of from about ?50° to about 0° and (2) contacting the reaction mixture of step (1) with a boron complexing agent.
- -
-
-
- Process for the preparation of latanoprost
-
Disclosed is a novel process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.
- -
-
-
- Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
-
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.
- -
-
-
- Storage-stable prostaglandin compositions
-
The use of polyethoxylated castor oils in prostaglandin compositions enhances the prostaglandin's chemical stability.
- -
-
-
- Method for increasing oxygen tension in the optic nerve and retina
-
There is disclosed a method for increasing retinal and optic nerve head oxygen tension by application of a composition comprising carbonic anhydrase inhibitors to the eye.
- -
-
-
- Storage-stable prostaglandin compositions
-
The use of polyethoxylated castor oils in prostaglandin compositions greatly enhances the prostaglandin's chemical stability.
- -
-
-
- Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
-
This invention relates a method for topical treatment of glaucoma or ocular hypertension by administration of an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure. The invention further relates to compositions comprising said prostaglandin derivatives in an ophthalmologically compatible carrier.
- -
-
-
- Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents
-
A series of phenyl-substituted analoques of prostaglandin F2α (PGF2α) were prepared and evaluated for ocular hypotensive effect and side effects in different animal models.In addition, the activity of the analogues on FP receptors was studied in vitro.The results were compared with those of PGF2α and its isopropyl ester.The phenyl-substituted PGF2α analogues exhibited good intraocular pressure reducing effect, were more selective, and exhibited a much higher therapeutic index in the eye than PGF2α or its isopropyl ester.The analogues exhibited high activity on FP receptors in a stereoselective manner for the 15a-hydroxyl group.
- Resul, Bahram,Stjernschantz, Johan,No, Kiyo,Liljebris, Charlotta,Selen, Goeran,et al.
-
p. 243 - 248
(2007/10/02)
-